查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1808038

癌症支持治療藥物市場（按藥物類別、癌症類型、給藥途徑、原廠藥類型、年齡層、適應症、護理環境、分銷管道和最終用戶分類）—2025-2030 年全球預測

Cancer Supportive Care Drugs Market by Drug Class, Cancer Type, Route Of Administration, Originator Type, Age Group, Indication, Care Setting, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計癌症支持治療藥物市場規模到 2024 年將達到 1.4437 億美元，到 2025 年將達到 1.5379 億美元，到 2030 年將達到 2.1387 億美元，複合年成長率為 6.76%。

主要市場統計數據
基準年2024年 1.4437億美元
預計2025年 1.5379億美元
預計2030年 2.1387億美元
複合年成長率（%） 6.76%

討論現代癌症治療過程中對支持性護理不斷變化的需求，以保持護理的連續性並改善患者的生活品質

癌症支持治療作為癌症治療的重要補充，不斷發展演變，注重維持患者功能、最大程度減少治療中斷，並透過持續治療改善生活品質。抗癌藥物治療的進步、對生存率的日益重視，以及對支持治療作為基於價值的癌症治療重要組成部分的廣泛認可，共同提升了預防或減輕噁心、感染疾病、骨骼併發症、貧血和疼痛等副作用的藥物的臨床和商業性重要性。隨著治療方法日益複雜，患者擴大在門診和家中接受治療，對有效的支持治療及其提供模式的需求日益成長，迫使相關人員重新審視治療的可及性、依從性和綜合醫療服務提供途徑。

檢驗獎勵支持性護理策略和相關人員激勵的臨床、商業和交付模式的轉變

癌症支持治療領域正在經歷變革性變革，這得益於臨床創新、不斷變化的交付模式以及支付方優先級的不斷變化，這些因素共同再形成了支持治療藥物的開發、應用和報銷。新型止吐策略和改良的造血藥物不斷湧現，同時還有骨質改良療法和種類不斷擴展的鎮痛選擇，所有這些都反映了人們對治療相關毒性和生存期需求的理解。這些治療方法進展，加上生物相似藥和學名藥的擴張，迫使現有製造商優先考慮生命週期管理、患者援助計劃和基本契約，以維護其臨床和商業性地位。

評估 2025 年關稅政策如何改變整個支持性照護社區的供應鏈動態、採購優先順序和取得途徑。

美國將於2025年實施的政策變革和關稅考量，將為整個支持性護理生態系統帶來新的營運和策略考量，並在製造、分銷和供應商層面產生累積影響。影響進口活性藥物原料藥、成品藥和醫療用品的關稅調整，更重視供應鏈規劃與服務成本分析。製造商被迫透過重新審視籌資策略、探索替代供應商關係以及加快二級供應商的資格審核來降低風險。這種重新調整將影響前置作業時間、庫存政策以及緊急生產能力的資本配置。

綜合多方面細分揭示了支持性護理市場的臨床重點、產品差異化和分銷策略

依藥物類別、癌症類型、給藥途徑、原廠藥類型、年齡層、適應症、護理環境、分銷管道和最終用戶進行細分，可以建立一個多維圖，用於了解臨床需求與商業機會和營運限制的交集。在藥物類別中，止吐藥、骨骼代謝改善劑、血液學藥物和疼痛管理藥物各自解決不同的臨床問題。止吐藥類別本身包括 5-HT3 拮抗劑、NK1 拮抗劑和Olanzapine理學亞類，而骨骼代謝改善劑包括雙磷酸鹽和 RANKL 抑制劑。血液學藥物包括促紅血球生成劑、骨髓保護劑和血小板生成素受體促效劑包括Darbepoetin和依伯汀等藥物。疼痛管理分為非鴉片類藥物和鴉片類藥物，非鴉片類藥物還包括對乙醯胺酚、輔助鎮痛藥和非類固醇消炎劑。

比較主要地區的監管、報銷和交付現實情況，以指導差異化的獲取和商業化策略

區域動態正在影響支持性護理藥物的開發、核准和交付方式，每個地區都有不同的法規環境、報銷模式和醫療服務基礎設施。在美洲，先進的癌症護理網路和強大的臨床試驗生態系統與支付方主導的成本控制並存，迫使製造商在投資於強力的患者支持和療效證據的同時，平衡創新與可負擔性。門診和居家醫療已顯著轉變，推動了對口服製劑、皮下給藥方案以及支持遠端監控和依從性服務的需求。

描述製造商、專業護理提供者和技術合作夥伴在塑造支持性護理服務方面的策略角色和競爭趨勢

關鍵產業參與者包括原廠製藥公司、生物相似藥和非專利製造商、專科藥房、受託製造廠商和醫療技術提供商，它們各自在支持性護理價值鏈中提供獨特的能力。原廠公司持續利用臨床差異化、緩釋性和綜合病患服務來捍衛其既有的特許專利權。同時，生物相似藥和非專利的參與企業透過提供低成本替代品並與批發商和專科經銷商建立策略聯盟，加大了競爭壓力。專科藥房和綜合護理提供者在協調家庭輸液、依從性監測和患者教育方面發揮越來越重要的作用，成為確保支持性護理連續性的關鍵接觸點。

優先考慮圍繞證據生成、供應鏈彈性、擴大患者權益倡導和靈活承包的策略行動，以確保競爭優勢

行業領導者應優先考慮一系列切實可行的舉措，以確保患者獲得治療，最佳化治療結果，並在不斷變化的支持性護理環境中保持商業性可行性。首先，將可靠的真實世界證據納入產品方案，以證明住院率、治療中斷率和支持性護理負擔在臨床上顯著降低，這將推動付款方參與並支持基於價值的合約。其次，透過供應商多元化、盡可能採用近岸外包以及緊急庫存規劃來增強供應鏈的韌性，可以降低政策變革和物流中斷帶來的脆弱性。第三，擴展患者支援服務，包括財務導航、遠端監控和家庭管理協調，可以提高藥物依從性和患者滿意度，從而增強差異化。

描述一種混合方法，該方法整合了臨床文獻、專家訪談和交叉檢驗分析，以深入了解實際的支持性護理。

本研究結合多種方法，整合了支持性治療相關的臨床、營運和商業性洞察。調查方法始於全面的二次研究，涵蓋同儕審查的臨床文獻、監管指導文件、公共公告和權威臨床實踐指南，以建立循證基礎。基準，還進行了一項研究，包括對腫瘤臨床醫生、專科藥劑師、醫療系統處方人員、付款人和行業高管進行結構化訪談，以了解臨床未滿足需求、獲取障礙和商業化策略方面的一線觀點。

總結整合策略如何決定不斷發展的支持性護理生態系統中的獲取和結果

越來越多的分析表明，支持性護理藥物是現代癌症治療的核心，影響著治療的連續性、患者體驗和醫療資源的利用。臨床創新，加上醫療服務向門診和居家模式的轉變，對製劑、物流和病患支援的需求日益成長。同時，政策發展和資費考量也帶來了新的營運限制，需要在採購、分銷和定價方面進行策略性調整。成功的相關人員將是那些整合嚴謹的真實世界證據、彈性供應鏈和以病人為中心的服務模式，並向付款人、提供者和病人展示價值的人。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章市場動態

  • 加速核准長效 G-CSF 生物相似藥，以加強化療嗜中性白血球低下症的治療
  • 整合數位健康平台來監測和改善患者對支持性護理的依從性
  • 擴大藥物基因組學檢測的應用，以個人化支持性止吐和鎮痛治療
  • 口服選擇性 NK-1 受體拮抗劑緩解化療引起的噁心的臨床開發
  • 使用吸入和經皮製劑減少化療引起的黏膜炎和黏膜毒性
  • 學名藥和生物相似藥的市場競爭日益激烈，降低了Pegfilgrastim的治療成本
  • 一種針對頑固性癌症疼痛和化療副作用的新型大麻素支持療法
  • 進行腫瘤高成本支持性護理生物製藥報銷的真實世界證據研究

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：2025年美國關稅的累積影響

第 8 章：癌症支持治療藥物市場（按藥物類別）

  • 止吐藥
    • 5-HT3拮抗劑
    • NK1拮抗劑
    • Olanzapine
  • 骨骼代謝改善劑
    • 雙磷酸鹽
    • RANKL抑制劑
  • 補血劑
    • 促紅血球生成因子
      • 達貝泊汀
      • 紅血球生成素
    • 骨髓保護劑
    • 血小板生成素受體促效劑
  • 疼痛管理藥物
    • 非鴉片類藥物
      • 乙醯胺酚
      • 輔助止痛藥
      • 非類固醇消炎劑（NSAID）
    • 鴉片類藥物

第9章 癌症支持治療藥物市場（按癌症類型）

  • 造血系統惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
    • 骨髓發育不良症候群
  • 固態腫瘤
    • 乳癌
    • 大腸直腸癌
    • 消化系統癌症
    • 頭頸癌
    • 肺癌
    • 卵巢癌
    • 攝護腺癌

第 10 章 癌症支持治療藥物市場（依給藥途徑）

  • 靜脈
  • 口服
  • 直腸
  • 皮下
  • 局部的
  • 經皮

第 11 章 癌症支持治療藥物市場（按原始藥物類型）

  • 生物相似藥
  • 品牌
  • 非專利的

第12章 癌症支持治療藥物市場（依年齡層）

  • 成人
  • 老年人
  • 孩子們

第13章 癌症支持治療藥物市場（按適應症）

  • 骨轉移相關事件
  • 惡病質和食慾不振
  • 癌症痛
  • 化療引起的噁心和嘔吐
    • 急性CINV
    • 特發性/難治性 CINV
    • 遲發性CINV
  • 腹瀉
  • 黏膜炎/口腔炎
  • 骨髓抑制
    • 化療引起的貧血
    • 化療引起的嗜中性白血球低下症

14. 癌症支持治療藥物市場（依護理環境）

  • 住院病人
  • 門診

第15章 癌症支持治療藥物市場（依通路）

  • 醫院藥房
  • 通訊/網路藥局
  • 零售藥局
  • 專業藥房

第16章 癌症支持治療藥物市場（依最終使用者）

  • 門診手術中心
  • 居家照護環境
  • 醫院
  • 癌症診所/輸液中心

第 17 章：美洲癌症支持治療藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

18. 歐洲、中東和非洲癌症支持治療藥物市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

19. 亞太地區癌症支持治療藥物市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第20章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Amgen Inc.
    • Novartis AG
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Fresenius Kabi AG
    • Heron Therapeutics, Inc.
    • Helsinn Healthcare SA
    • AstraZeneca plc
    • Ipsen SA
    • Dr. Reddy's Laboratories Ltd.
    • Acacia Pharma Group Plc
    • Fresenius SE & Co. KGaA
    • Lupin Limited
    • Daiichi Sankyo Company, Limited
    • APR Applied Pharma Research SA by Relief Therapeutics Holding AG
    • Abbott Laboratories
    • Accord Healthcare Limited
    • Coherus BioSciences, Inc.

第21章 研究人工智慧

第22章 研究統計

第23章 研究聯絡人

第24章 研究報導

第25章 附錄

Product Code: MRR-450A0628C601

The Cancer Supportive Care Drugs Market was valued at USD 144.37 million in 2024 and is projected to grow to USD 153.79 million in 2025, with a CAGR of 6.76%, reaching USD 213.87 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 144.37 million
Estimated Year [2025] USD 153.79 million
Forecast Year [2030] USD 213.87 million
CAGR (%) 6.76%

Framing the evolving imperative for supportive therapies that preserve treatment continuity and enhance patient quality of life across modern oncology care

Cancer supportive care continues to evolve as a critical complement to oncologic therapy, focusing on preserving patient function, minimizing treatment interruptions, and improving quality of life across the treatment continuum. Advances in anticancer therapeutics, rising emphasis on survivorship, and broader recognition of supportive care as an integral component of value-based oncology care have collectively elevated the clinical and commercial importance of drugs that prevent or mitigate adverse effects such as nausea, infection, bone complications, anemia, and pain. As treatment regimens become more complex and patients increasingly receive therapy in outpatient or home settings, the need for effective supportive agents and delivery models has intensified, prompting stakeholders to re-examine pathways for access, adherence, and integrated care delivery.

Regulatory attention and payer scrutiny have shifted the conversation from episodic symptom control to longitudinal management strategies that reduce hospitalizations and enable continued cancer-directed therapy. Meanwhile, technological enablers such as telemedicine, remote monitoring, and digital adherence tools are being woven into supportive care pathways to detect complications early and to triage interventions. These developments are influencing clinical practice guidelines, hospital formularies, and procurement strategies, while simultaneously shaping expectations among patients and caregivers for a higher standard of symptom management. Consequently, supportive care drugs are no longer ancillary commodities but constitute strategic assets in optimizing treatment outcomes and sustaining healthcare system efficiencies.

Examining the clinical, commercial, and delivery model transformations that are redefining supportive care strategies and stakeholder incentives

The landscape of cancer supportive care has undergone transformative shifts driven by clinical innovation, delivery model changes, and evolving payer priorities that collectively reshape how supportive medicines are developed, adopted, and reimbursed. Novel antiemetic strategies and refinements in hematopoietic agents are emerging alongside an expanding portfolio of bone-modifying therapies and diversified analgesic options, all of which reflect a more nuanced understanding of treatment-related toxicities and survivorship needs. These therapeutic advances are complemented by an expansion of biosimilars and generics that force incumbent manufacturers to prioritize lifecycle management, patient support programs, and value-based contracting to defend clinical and commercial positioning.

Concurrent shifts in care delivery have profound implications. An acceleration of outpatient infusion, homecare services, and remote monitoring has prompted manufacturers and providers to redesign packaging, dosing regimens, and adherence support to accommodate decentralized treatment environments. Payer emphasis on outcomes and cost containment is incentivizing real-world evidence generation and performance-based agreements, which in turn influence clinical guideline adoption and formulary decisions. Supply chain resilience and manufacturing flexibility have become strategic priorities in light of geopolitical pressures and episodic disruptions, increasing interest in diversified sourcing, nearshoring, and capacity partnering with contract manufacturers. Taken together, these shifts signal a more integrated, multidisciplinary approach to supportive care that aligns clinical efficacy with operational feasibility and economic sustainability.

Assessing how tariff policy shifts in 2025 altered supply chain dynamics, procurement priorities, and access pathways across supportive care stakeholders

Policy changes and tariff considerations introduced in the United States in 2025 have injected a new set of operational and strategic calculations across the supportive care ecosystem, with cumulative impacts felt at the manufacturing, distribution, and provider levels. Tariff adjustments affecting imported active pharmaceutical ingredients, finished formulations, and medical supplies have increased the emphasis on supply chain mapping and cost-to-serve analysis. Manufacturers have been prompted to reassess sourcing strategies, pursue alternative supplier relationships, and accelerate qualification of secondary suppliers to mitigate exposure. This recalibration has implications for lead times, inventory policies, and capital allocation for contingency manufacturing capacity.

These policy-induced cost pressures have reverberated through distribution channels and procurement cycles, elevating negotiation intensity between manufacturers, distributors, and payers. Health systems and specialty pharmacies have intensified their focus on formulary optimization and total cost-of-care calculations to preserve access while managing budgets. At the clinical interface, providers have become more attentive to therapeutic equivalence and to opportunities for substituting lower-cost generics or biosimilars where clinically appropriate. Patient support mechanisms have also been affected as companies re-evaluate copay assistance programs and logistical support for home administration to ensure affordability and continuity of therapy.

In response to tariff-driven uncertainty, some stakeholders have advocated for policy engagement and collaborative solutions, such as tariff exemptions for critical medical inputs, incentives for domestic manufacturing, and streamlined regulatory pathways for rapid supplier qualification. These strategies aim to balance the goals of national industrial policy with the imperative to maintain patient access and clinical quality. Looking ahead, organizations that proactively adapt procurement, contractual frameworks, and patient support models will be better positioned to navigate sustained policy variability while safeguarding treatment continuity for vulnerable patient populations.

Integrating multi-dimensional segmentation to illuminate clinical priorities, product differentiation, and distribution strategies across supportive care markets

Segmentation across drug class, cancer type, route of administration, originator type, age group, indication, care setting, distribution channel, and end user creates a multidimensional map for understanding where clinical needs intersect with commercial opportunity and operational constraints. Within drug class, antiemetics, bone-modifying agents, hematopoietic agents, and pain management agents each address distinct clinical problems; the antiemetic category itself includes pharmacologic subclasses such as 5-HT3 antagonists, NK1 antagonists, and olanzapine, while bone-modifying therapies encompass bisphosphonates and RANKL inhibitors. Hematopoietic support spans erythropoiesis stimulating agents, myeloprotection agents, and thrombopoietin receptor agonists, and erythropoiesis stimulating agents are characterized by formulations such as darbepoetin and epoetin. Pain management divides into non-opioid and opioid approaches, with non-opioids further characterized by acetaminophen, adjuvant analgesics, and nonsteroidal anti-inflammatory drugs.

Cancer type segmentation distinguishes hematologic malignancies and solid tumors, with hematologic categories covering leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes, while solid tumors include breast, colorectal, gastrointestinal, head and neck, lung, ovarian, and prostate cancers, each of which presents unique supportive care priorities and guideline-driven interventions. Route of administration intersects with care setting considerations, spanning intravenous, oral, rectal, subcutaneous, topical, and transdermal modalities, and prompting different patient education, adherence, and logistics needs. Originator type-biosimilar, branded, and generic-shapes pricing dynamics and contracting strategies, while age-group segmentation across adult, geriatric, and pediatric populations demands tailored dosing, safety monitoring, and caregiver support.

Indication-based segmentation addresses complications such as bone metastases related events, cachexia and anorexia, cancer pain, chemotherapy-induced nausea and vomiting with its acute, breakthrough/refractory, and delayed subcategories, diarrhea, mucositis and stomatitis, and myelosuppression including chemotherapy-induced anemia and neutropenia; each indication imposes specific efficacy, safety, and delivery expectations. Distribution channel and end-user segmentation illuminate commercial pathways, with hospital pharmacies, mail-order and online pharmacies, retail pharmacies, and specialty pharmacies interacting with ambulatory surgery centers, homecare settings, hospitals, and oncology clinics and infusion centers. Integrating these segmentation lenses enables stakeholders to prioritize product development, align patient support programs, and design distribution strategies that reflect clinical workflows and payer requirements.

Comparing the regulatory, reimbursement, and delivery realities across major regions to guide differentiated access and commercialization strategies

Regional dynamics shape how supportive care drugs are developed, approved, and delivered, with each geography presenting distinct regulatory environments, reimbursement paradigms, and care delivery infrastructures. In the Americas, advanced oncology care networks and strong clinical trial ecosystems coexist with payer-driven cost containment, driving manufacturers to balance innovation with affordability and to invest in robust patient support and outcomes evidence. Shifts toward outpatient and home-based care are pronounced, amplifying demand for oral formulations, subcutaneous options, and services that enable remote monitoring and adherence support.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and diverse market access pathways require differentiated strategies that account for national reimbursement rules, tendering mechanisms, and varying levels of healthcare infrastructure. Manufacturers often pursue regionally tailored evidence generation and pricing strategies to secure formulary inclusion, and partnerships with regional distributors and specialty pharmacies are common to bridge logistical gaps and enhance reach. In the Asia-Pacific region, rapid healthcare modernization, expanding oncology service capacity, and growing attention to biosimilar adoption create both opportunities and complexities. Regulatory harmonization efforts coexist with country-specific procurement models, and manufacturers are incentivized to develop flexible supply arrangements and locally relevant patient support services to accelerate uptake and sustain access amid evolving payer expectations.

Profiling the strategic roles and competitive moves of manufacturers, specialty providers, and technology partners shaping supportive care delivery

Key industry participants span originator pharmaceutical companies, biosimilar manufacturers, generic producers, specialty pharmacies, contract manufacturing organizations, and healthcare technology providers, each contributing distinct capabilities to the supportive care value chain. Originator firms continue to leverage clinical differentiation, extended-release formulations, and integrated patient services to defend established franchises, while biosimilar and generic entrants intensify competitive pressure by offering lower-cost alternatives and by pursuing strategic partnerships with wholesalers and specialty distributors. Specialty pharmacies and integrated care providers play an increasingly important role in coordinating home infusion, adherence monitoring, and patient education, serving as critical touchpoints for ensuring continuity of supportive therapy.

Contract manufacturing and outsourcing partners have expanded capacity to meet demand for flexible production and regulatory compliance, enabling companies to respond more rapidly to supply disruptions and to local content requirements. Technology providers supplying remote monitoring, telehealth platforms, and digital adherence tools are forging collaborations with manufacturers and providers to support decentralized care models. Across this ecosystem, leading organizations are distinguishing themselves through investments in real-world evidence, comprehensive patient support programs that address affordability and logistics, and value-based contracting approaches that align reimbursement with clinical outcomes. These strategic moves reflect a broader emphasis on integrated care pathways, where drug efficacy must be matched by delivery capabilities and demonstrable impact on patient-relevant endpoints.

Prioritizing strategic actions on evidence generation, supply chain resilience, patient support expansion, and flexible contracting to secure competitive advantage

Industry leaders should prioritize a set of actionable initiatives to secure access, optimize patient outcomes, and sustain commercial viability in a changing supportive care environment. First, embedding robust real-world evidence generation into product programs will facilitate payer engagement and support value-based agreements by demonstrating clinically meaningful reductions in hospitalizations, treatment interruptions, and supportive care burden. Second, strengthening supply chain resilience through supplier diversification, nearshoring where feasible, and contingency inventory planning will reduce vulnerability to policy shifts and logistic disruptions. Third, expanding patient support services that encompass financial navigation, remote monitoring, and coordinated home administration will improve adherence and patient satisfaction while reinforcing differentiation.

In parallel, organizations should adopt flexible pricing and contracting frameworks that account for total cost of care and enable outcome-based arrangements with payers and providers. Product teams must align formulation development and packaging innovations with the realities of outpatient and home care to enhance usability and safety. Strategic alliances with specialty pharmacies, homecare providers, and technology vendors can accelerate adoption of decentralized care models and provide seamless patient experiences. Executing these recommendations requires cross-functional coordination across commercial, medical, regulatory, and supply chain teams, and a willingness to pilot new commercial models in partnership with payers and provider systems to generate the evidence and operational learnings necessary for scale.

Explaining the mixed-methods approach that combines clinical literature, expert interviews, and cross-validated analysis to produce actionable supportive care insights

This research integrates a multi-method approach to synthesize clinical, operational, and commercial insights relevant to supportive care therapeutics. The methodology begins with comprehensive secondary research drawn from peer-reviewed clinical literature, regulatory guidance documents, public policy announcements, and authoritative clinical practice guidelines to establish an evidence-based foundation. This baseline was complemented by primary research consisting of structured interviews with oncology clinicians, specialty pharmacists, health system formulary decision-makers, payers, and industry executives to capture frontline perspectives on clinical unmet needs, access barriers, and commercialization tactics.

Analytical methods included qualitative thematic analysis to surface recurring themes and strategic priorities, and cross-validation using triangulation across data sources to ensure consistency and reduce bias. Segmentation frameworks were constructed by mapping therapeutic classes, clinical indications, administration routes, and care settings to real-world care pathways, allowing for scenario analysis of distribution and access models. Validation steps involved iterative review with independent clinical advisors and supply chain specialists to refine assumptions about operational feasibility and to corroborate strategic interpretations. Where applicable, regulatory and policy analyses were incorporated to contextualize potential impacts on procurement, manufacturing, and patient access.

Summarizing how integrated clinical, operational, and commercial strategies will determine access and outcomes in the evolving supportive care ecosystem

The cumulative analysis underscores that supportive care drugs are central to contemporary oncology practice, influencing treatment continuity, patient experience, and healthcare resource utilization. Clinical innovation, coupled with shifts in care delivery toward outpatient and home-based models, has elevated requirements for formulations, logistics, and patient support. Concurrently, policy developments and tariff considerations have introduced new operational constraints that necessitate strategic adaptation across sourcing, distribution, and pricing. Stakeholders that succeed will be those that integrate rigorous real-world evidence, resilient supply chains, and patient-centric service models to demonstrate value to payers, providers, and patients.

Looking ahead, the convergence of clinical, commercial, and operational trends points to a future in which supportive care strategies are tightly aligned with broader oncology objectives: enabling sustained delivery of cancer-directed therapies, mitigating adverse events, and optimizing total cost of care. Organizations that proactively reconfigure their portfolios, partnerships, and evidence-generation strategies to reflect decentralized care realities and evolving reimbursement expectations will be best positioned to deliver meaningful improvements in patient outcomes while sustaining long-term competitiveness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Accelerated approval of long-acting G-CSF biosimilars enhancing neutropenia management in chemotherapy
  • 5.2. Integration of digital health platforms to monitor and improve patient adherence to supportive care regimens
  • 5.3. Expanding use of pharmacogenomic testing to personalize antiemetic and analgesic supportive care therapies
  • 5.4. Clinical development of oral selective NK-1 receptor antagonists for multidrug chemotherapy-induced nausea relief
  • 5.5. Adoption of inhaled and transdermal formulations to mitigate chemotherapy-induced mucositis and mucosal toxicity
  • 5.6. Growing market competition from generic and biosimilar pegfilgrastim alternatives reducing treatment costs
  • 5.7. Emerging cannabinoid-based supportive therapies targeting refractory cancer pain and chemotherapy side effects
  • 5.8. Implementation of real-world evidence studies for reimbursement of high-cost supportive care biologics in oncology

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Cancer Supportive Care Drugs Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Antiemetics
    • 8.2.1. 5-HT3 Antagonists
    • 8.2.2. NK1 Antagonists
    • 8.2.3. Olanzapine
  • 8.3. Bone-Modifying Agents
    • 8.3.1. Bisphosphonates
    • 8.3.2. RANKL Inhibitors
  • 8.4. Hematopoietic Agents
    • 8.4.1. Erythropoiesis Stimulating Agents
      • 8.4.1.1. Darbepoetin
      • 8.4.1.2. Epoetin
    • 8.4.2. Myeloprotection Agents
    • 8.4.3. Thrombopoietin Receptor Agonists
  • 8.5. Pain Management Agents
    • 8.5.1. Non-Opioids
      • 8.5.1.1. Acetaminophen
      • 8.5.1.2. Adjuvant Analgesics
      • 8.5.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.5.2. Opioids

9. Cancer Supportive Care Drugs Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Hematologic Malignancies
    • 9.2.1. Leukemias
    • 9.2.2. Lymphomas
    • 9.2.3. Multiple Myeloma
    • 9.2.4. Myelodysplastic Syndromes
  • 9.3. Solid Tumors
    • 9.3.1. Breast Cancer
    • 9.3.2. Colorectal Cancer
    • 9.3.3. Gastrointestinal Cancers
    • 9.3.4. Head And Neck Cancer
    • 9.3.5. Lung Cancer
    • 9.3.6. Ovarian Cancer
    • 9.3.7. Prostate Cancer

10. Cancer Supportive Care Drugs Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Rectal
  • 10.5. Subcutaneous
  • 10.6. Topical
  • 10.7. Transdermal

11. Cancer Supportive Care Drugs Market, by Originator Type

  • 11.1. Introduction
  • 11.2. Biosimilar
  • 11.3. Branded
  • 11.4. Generic

12. Cancer Supportive Care Drugs Market, by Age Group

  • 12.1. Introduction
  • 12.2. Adult
  • 12.3. Geriatric
  • 12.4. Pediatric

13. Cancer Supportive Care Drugs Market, by Indication

  • 13.1. Introduction
  • 13.2. Bone Metastases Related Events
  • 13.3. Cachexia & Anorexia
  • 13.4. Cancer Pain
  • 13.5. Chemotherapy-Induced Nausea & Vomiting
    • 13.5.1. Acute CINV
    • 13.5.2. Breakthrough/Refractory CINV
    • 13.5.3. Delayed CINV
  • 13.6. Diarrhea
  • 13.7. Mucositis And Stomatitis
  • 13.8. Myelosuppression
    • 13.8.1. Chemotherapy-Induced Anemia
    • 13.8.2. Chemotherapy-Induced Neutropenia

14. Cancer Supportive Care Drugs Market, by Care Setting

  • 14.1. Introduction
  • 14.2. Inpatient
  • 14.3. Outpatient

15. Cancer Supportive Care Drugs Market, by Distribution Channel

  • 15.1. Introduction
  • 15.2. Hospital Pharmacies
  • 15.3. Mail-Order And Online Pharmacies
  • 15.4. Retail Pharmacies
  • 15.5. Specialty Pharmacies

16. Cancer Supportive Care Drugs Market, by End User

  • 16.1. Introduction
  • 16.2. Ambulatory Surgery Centers
  • 16.3. Homecare Settings
  • 16.4. Hospitals
  • 16.5. Oncology Clinics And Infusion Centers

17. Americas Cancer Supportive Care Drugs Market

  • 17.1. Introduction
  • 17.2. United States
  • 17.3. Canada
  • 17.4. Mexico
  • 17.5. Brazil
  • 17.6. Argentina

18. Europe, Middle East & Africa Cancer Supportive Care Drugs Market

  • 18.1. Introduction
  • 18.2. United Kingdom
  • 18.3. Germany
  • 18.4. France
  • 18.5. Russia
  • 18.6. Italy
  • 18.7. Spain
  • 18.8. United Arab Emirates
  • 18.9. Saudi Arabia
  • 18.10. South Africa
  • 18.11. Denmark
  • 18.12. Netherlands
  • 18.13. Qatar
  • 18.14. Finland
  • 18.15. Sweden
  • 18.16. Nigeria
  • 18.17. Egypt
  • 18.18. Turkey
  • 18.19. Israel
  • 18.20. Norway
  • 18.21. Poland
  • 18.22. Switzerland

19. Asia-Pacific Cancer Supportive Care Drugs Market

  • 19.1. Introduction
  • 19.2. China
  • 19.3. India
  • 19.4. Japan
  • 19.5. Australia
  • 19.6. South Korea
  • 19.7. Indonesia
  • 19.8. Thailand
  • 19.9. Philippines
  • 19.10. Malaysia
  • 19.11. Singapore
  • 19.12. Vietnam
  • 19.13. Taiwan

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. Amgen Inc.
    • 20.3.2. Novartis AG
    • 20.3.3. Pfizer Inc.
    • 20.3.4. F. Hoffmann-La Roche Ltd.
    • 20.3.5. Johnson & Johnson Services, Inc.
    • 20.3.6. Sanofi S.A.
    • 20.3.7. GlaxoSmithKline plc
    • 20.3.8. Teva Pharmaceutical Industries Ltd.
    • 20.3.9. Viatris Inc.
    • 20.3.10. Fresenius Kabi AG
    • 20.3.11. Heron Therapeutics, Inc.
    • 20.3.12. Helsinn Healthcare SA
    • 20.3.13. AstraZeneca plc
    • 20.3.14. Ipsen S.A.
    • 20.3.15. Dr. Reddy's Laboratories Ltd.
    • 20.3.16. Acacia Pharma Group Plc
    • 20.3.17. Fresenius SE & Co. KGaA
    • 20.3.18. Lupin Limited
    • 20.3.19. Daiichi Sankyo Company, Limited
    • 20.3.20. APR Applied Pharma Research S.A. by Relief Therapeutics Holding AG
    • 20.3.21. Abbott Laboratories
    • 20.3.22. Accord Healthcare Limited
    • 20.3.23. Coherus BioSciences, Inc.

21. ResearchAI

22. ResearchStatistics

23. ResearchContacts

24. ResearchArticles

25. Appendix

LIST OF FIGURES

  • FIGURE 1. CANCER SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 26. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 30. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 31. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 33. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHAI
  • FIGURE 34. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHSTATISTICS
  • FIGURE 35. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHCONTACTS
  • FIGURE 36. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOPROTECTION AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOPROTECTION AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THROMBOPOIETIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THROMBOPOIETIN RECEPTOR AGONISTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADJUVANT ANALGESICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LEUKEMIAS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LYMPHOMAS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GASTROINTESTINAL CANCERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CACHEXIA & ANOREXIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CACHEXIA & ANOREXIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER PAIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE CINV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE CINV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAKTHROUGH/REFRACTORY CINV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAKTHROUGH/REFRACTORY CINV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED CINV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED CINV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MUCOSITIS AND STOMATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MUCOSITIS AND STOMATITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED ANEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED ANEMIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MAIL-ORDER AND ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MAIL-ORDER AND ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONCOLOGY CLINICS AND INFUSION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONCOLOGY CLINICS AND INFUSION CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 179. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 181. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
  • TABLE 183. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 185. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2025-2030 (USD MILLION)
  • TABLE 187. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 189. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
  • TABLE 191. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2025-2030 (USD MILLION)
  • TABLE 193. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
  • TABLE 197. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
  • TABLE 199. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 201. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 205. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 207. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
  • TABLE 209. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2025-2030 (USD MILLION)
  • TABLE 211. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025-2030 (USD MILLION)
  • TABLE 213. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 217. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 259. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 261. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
  • TABLE 262. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
  • TABLE 263. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 265. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOPOIETIC AGENTS, 2025-2030 (USD MILLION)
  • TABLE 267. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 268. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
  • TABLE 269. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
  • TABLE 271. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 272. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-OPIOIDS, 2025-2030 (USD MILLION)
  • TABLE 273. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 276. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
  • TABLE 277. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 278. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
  • TABLE 279. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 281. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORIGINATOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 283. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
  • TABLE 285. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 287. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
  • TABLE 288. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
  • TABLE 289. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 290. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MYELOSUPPRESSION, 2025-2030 (USD MILLION)
  • TABLE 291. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2018-2024 (USD MILLION)
  • TABLE 292. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CARE SETTING, 2025-2030 (USD MILLION)
  • TABLE 293. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 295. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)

TABLE